目的 探讨前列舒通胶囊联合非那雄胺治疗良性前列腺增生症的临床疗效。方法 选取2014年8月-2015年8月什邡市人民医院泌尿外科收治的良性前列腺增生症患者88例,随机分为对照组和治疗组,每组各44例。对照组口服非那雄胺片5 mg/次,1次/d。治疗组在对照组治疗基础上口服前列舒通胶囊,3粒/次,3次/d。两组患者均连续治疗8周。观察两组的临床疗效,同时比较治疗前后两组国际前列腺症状评分(IPSS)、前列腺体积(PV)、膀胱残余尿量(RV)、最大尿流率(Q_max)的变化情况。结果 治疗后,对照组和治疗组的总有效率分别为88.64%、95.45%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者IPSS评分、PV、RV均较治疗前明显降低,而Q_max均较治疗前增高,同组治疗前后差异有统计学意义(P<0.05);且治疗组这些观察指标的改善程度优于对照组,两组比较差异有统计学意义(P<0.05)。结论 前列舒通胶囊联合非那雄胺治疗良性前列腺增生症具有较好的临床疗效,能够显著改善患者的临床症状,降低RV、PV,具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Qianlie Shutong Capsules combined with finasteride in treatment of benign prostatic hyperplasia.Methods Patients (88 cases) with benign prostatic hyperplasia in Department of Urinary Surgery of Shifang People's Hospital from August 2014 to August 2015 were randomly divided into control and treatment groups. Each group had 44 cases. The patients in the control group were poadministered with Finasteride Tablets, 5 mg/time, once daily. The patients in the treatment group were poadministered with Qianlie Shutong Capsules on the basis of the control group, 3 grains/time, three times daily. The patients in two groups were treated for eight weeks. After treatment, the efficacy was evaluated, and the changes of IPSS scores, PV, RV, and Q_max in two groups were compared.Results After treatment, the efficacies in the control and treatment groups were 88.64% and 95.45%, respectively, and there were differences between two groups (P < 0.05). After treatment, IPSS scores, PV, and RV were significantly decreased, and Q_max was significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05).Conclusion Qianlie Shutong Capsules combined with finasteride has clinical curative effect in treatment of benign prostatic hyperplasia, and can significantly improve the clinical symptoms, and reduce the RV and PV, which has a certain clinical application value.